The price of Surgery Partners Inc (NASDAQ: SGRY) closed at $27.70 in the last session, up 0.65% from day before closing price of $27.52. In other words, the price has increased by $+0.18 from its previous closing price. On the day, 1239868 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
We take a closer look at SGRY’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 17.90 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 17.11. For the most recent quarter (mrq), Quick Ratio is recorded 1.57 and its Current Ratio is at 1.71. In the meantime, Its Debt-to-Equity ratio is 1.54 whereas as Long-Term Debt/Eq ratio is at 1.48.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Barclays on March 06, 2024, initiated with a Equal Weight rating and assigned the stock a target price of $35.
On November 14, 2023, TD Cowen Upgraded its rating to Outperform which previously was Market Perform and also lowered its target price recommendation from $39 to $35.
BofA Securities Upgraded its Neutral to Buy on June 02, 2023, whereas the target price for the stock was revised from $42 to $45.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 14 ’24 when Doherty David T sold 721 shares for $28.59 per share. The transaction valued at 20,613 led to the insider holds 95,719 shares of the business.
Evans Jason Eric sold 4,840 shares of SGRY for $143,796 on Mar 13 ’24. The Chief Executive Officer now owns 459,670 shares after completing the transaction at $29.71 per share. On Mar 12 ’24, another insider, Owens Bradley R., who serves as the National Group President of the company, sold 2,783 shares for $29.82 each. As a result, the insider received 82,989 and left with 78,338 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SGRY now has a Market Capitalization of 3.48B and an Enterprise Value of 6.35B. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.28 while its Price-to-Book (P/B) ratio in mrq is 1.76. Its current Enterprise Value per Revenue stands at 2.31 whereas that against EBITDA is 14.23.
Stock Price History:
Over the past 52 weeks, SGRY has reached a high of $45.79, while it has fallen to a 52-week low of $22.05. The 50-Day Moving Average of the stock is 31.66, while the 200-Day Moving Average is calculated to be 33.11.
Shares Statistics:
According to the various share statistics, SGRY traded on average about 954.88K shares per day over the past 3-months and 837.98k shares per day over the past 10 days. A total of 126.59M shares are outstanding, with a floating share count of 73.01M. Insiders hold about 42.33% of the company’s shares, while institutions hold 66.12% stake in the company. Shares short for SGRY as of Feb 29, 2024 were 7.76M with a Short Ratio of 8.13, compared to 7.78M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 6.13% and a Short% of Float of 15.94%.
Earnings Estimates
The company has 10 analysts who recommend its stock at the moment. On average, analysts expect EPS of $0.08 for the current quarter, with a high estimate of $0.13 and a low estimate of $0.02, while EPS last year was $0.08. The consensus estimate for the next quarter is $0.19, with high estimates of $0.23 and low estimates of $0.13.
Analysts are recommending an EPS of between $1.12 and $0.78 for the fiscal current year, implying an average EPS of $1. EPS for the following year is $1.28, with 11 analysts recommending between $1.49 and $1.16.
Revenue Estimates
According to 9 analysts, the current quarter’s revenue is expected to be $702.85M. It ranges from a high estimate of $726.82M to a low estimate of $688M. As of the current estimate, Surgery Partners Inc’s year-ago sales were $666.2M, an estimated increase of 5.50% from the year-ago figure. For the next quarter, 9 analysts are estimating revenue of $730.98M, an increase of 9.50% over than the figure of $5.50% in the same quarter last year. There is a high estimate of $745.27M for the next quarter, whereas the lowest estimate is $708M.
A total of 10 analysts have provided revenue estimates for SGRY’s current fiscal year. The highest revenue estimate was $3.02B, while the lowest revenue estimate was $3B, resulting in an average revenue estimate of $3.01B. In the same quarter a year ago, actual revenue was $2.74B, up 9.60% from the average estimate. Based on 10 analysts’ estimates, the company’s revenue will be $3.27B in the next fiscal year. The high estimate is $3.32B and the low estimate is $3.24B. The average revenue growth estimate for next year is up 8.80% from the average revenue estimate for this year.
